Treat juvenile idiopathic arthritis to remission target: task force

Major advances in therapy for juvenile idiopathic arthritis (JIA) mean that children should be treated to a target of clinical remission, an international task force has advised.

Although there have been no clinical trials of treat-to-target in JIA, the consensus of a task force of 30 expert paediatric rheumatologists is that the approach, adopted for many adult rheumatic diseases, must be extended to children.

The task force, which includes Melbourne paediatric rheumatologist, Dr Jonathan Akikusa, provides six over-arching principles and eight recommendations in its report,